Multi-omic approach identifies a transcriptional network coupling innate immune response to proliferation in the blood of COVID-19 cancer patients.
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
29 10 2021
29 10 2021
Historique:
received:
11
07
2021
accepted:
08
10
2021
revised:
04
10
2021
entrez:
30
10
2021
pubmed:
31
10
2021
medline:
12
11
2021
Statut:
epublish
Résumé
Clinical outcomes of COVID-19 patients are worsened by the presence of co-morbidities, especially cancer leading to elevated mortality rates. SARS-CoV-2 infection is known to alter immune system homeostasis. Whether cancer patients developing COVID-19 present alterations of immune functions which might contribute to worse outcomes have so far been poorly investigated. We conducted a multi-omic analysis of immunological parameters in peripheral blood mononuclear cells (PBMCs) of COVID-19 patients with and without cancer. Healthy donors and SARS-CoV-2-negative cancer patients were also included as controls. At the infection peak, cytokine multiplex analysis of blood samples, cytometry by time of flight (CyTOF) cell population analyses, and Nanostring gene expression using Pancancer array on PBMCs were performed. We found that eight pro-inflammatory factors (IL-6, IL-8, IL-13, IL-1ra, MIP-1a, IP-10) out of 27 analyzed serum cytokines were modulated in COVID-19 patients irrespective of cancer status. Diverse subpopulations of T lymphocytes such as CD8
Identifiants
pubmed: 34716309
doi: 10.1038/s41419-021-04299-y
pii: 10.1038/s41419-021-04299-y
pmc: PMC8553595
doi:
Substances chimiques
Antibodies, Viral
0
Cytokines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1019Informations de copyright
© 2021. The Author(s).
Références
Nat Rev Cancer. 2016 Mar;16(3):131-44
pubmed: 26911188
Brief Bioinform. 2021 Mar 22;22(2):1279-1290
pubmed: 33169132
J Hematol Oncol. 2021 May 17;14(1):81
pubmed: 34001183
Front Med (Lausanne). 2020 Sep 25;7:558545
pubmed: 33102499
Oncoimmunology. 2020 May 5;9(1):1760686
pubmed: 32923119
Front Immunol. 2019 Jan 08;9:3086
pubmed: 30671058
J Hematol Oncol. 2021 Jul 29;14(1):119
pubmed: 34325728
PLoS One. 2008 Apr 23;3(4):e2047
pubmed: 18431504
Front Immunol. 2020 Sep 30;11:595739
pubmed: 33117408
Front Immunol. 2020 Oct 14;11:580237
pubmed: 33154753
J Exp Clin Cancer Res. 2020 Sep 23;39(1):200
pubmed: 32967703
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
Oncogene. 2009 Aug 13;28(32):2873-81
pubmed: 19543322
Nat Commun. 2020 Mar 26;11(1):1562
pubmed: 32218434
Cancer Cell. 2018 Aug 13;34(2):286-297.e10
pubmed: 30057145
Biochim Biophys Acta Gene Regul Mech. 2017 May;1860(5):604-616
pubmed: 27939755
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Nat Med. 2021 Jul;27(7):1280-1289
pubmed: 34017137
Transl Oncol. 2021 Jan;14(1):100943
pubmed: 33204385
J Clin Invest. 2020 Dec 1;130(12):6290-6300
pubmed: 32784290
Sci Immunol. 2020 Sep 17;5(51):
pubmed: 32943497
J Reprod Immunol. 2020 Nov;142:103213
pubmed: 33080435
Cancer Discov. 2020 Jul;10(7):935-941
pubmed: 32357994
Clin Transl Oncol. 2020 Dec;22(12):2364-2368
pubmed: 32449128
Cold Spring Harb Symp Quant Biol. 2013;78:105-16
pubmed: 24092468
Nat Med. 2020 May;26(5):665-671
pubmed: 32405058
Nat Cancer. 2020 Oct;1(10):965-975
pubmed: 35121871
J Immunother Cancer. 2020 Jul;8(2):
pubmed: 32675312
Eur J Pharmacol. 2021 Jan 5;890:173741
pubmed: 33227287
Cancer Cell. 2020 Nov 9;38(5):629-646
pubmed: 33049215
Cell. 2020 Aug 6;182(3):685-712.e19
pubmed: 32645325
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
Cancer Cell. 2021 Feb 8;39(2):257-275.e6
pubmed: 33476581
Chin Med J (Engl). 2020 May 5;133(9):1087-1095
pubmed: 32358325
Signal Transduct Target Ther. 2020 Mar 27;5(1):33
pubmed: 32296069
Cell Death Dis. 2020 Jun 8;11(6):429
pubmed: 32513989
Nat Med. 2020 Oct;26(10):1623-1635
pubmed: 32807934
Front Immunol. 2019 May 24;10:1176
pubmed: 31178872
JAMA Oncol. 2021 Feb 1;7(2):220-227
pubmed: 33300956
J Exp Clin Cancer Res. 2020 Jun 16;39(1):112
pubmed: 32546182
Front Immunol. 2020 May 01;11:827
pubmed: 32425950
J Clin Invest. 2020 Sep 1;130(9):4694-4703
pubmed: 32463803
FEBS J. 2015 Jan;282(2):224-58
pubmed: 25393971
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
Cell. 2020 Oct 1;183(1):4-10
pubmed: 32979319
Eur J Cancer. 2020 Dec;141:92-104
pubmed: 33130550
J Clin Invest. 2007 May;117(5):1137-46
pubmed: 17476343
Nature. 2007 May 24;447(7143):407-12
pubmed: 17522673
Ann Transl Med. 2020 Sep;8(18):1145
pubmed: 33240994
Sci Immunol. 2021 Aug 10;6(62):
pubmed: 34376481
Science. 2020 Aug 7;369(6504):718-724
pubmed: 32661059